8-K: 89bio Reports First Quarter 2025 Financial Results and Provides Corporate Updates

89bio announces its Q1 2025 financial results, highlighting progress in Phase 3 trials for MASH and SHTG, and a strong cash position following a recent equity offering.

Summary

• 89bio reported its financial results for the first quarter ended March 31, 2025.
• The company is focused on developing therapies for liver and cardiometabolic diseases.
• Topline histology data from the ENLIGHTEN-Fibrosis trial is expected in the first half of 2027.
• Topline histology data from the ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 2028.
• The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) has been fully enrolled, with topline data expected in the first quarter of 2026.
• As of March 31, 2025, the company had $638.8 million in cash, cash equivalents, and marketable securities.
• A follow-on equity offering in Q1 2025 generated gross proceeds of $287.5 million.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong cash position, progress in Phase 3 trials, and positive management comments. However, the increased net loss and R&D expenses temper the overall sentiment.

Positives

• The company has a strong cash position of $638.8 million.
• The ENTRUST trial is fully enrolled and on track for topline data in Q1 2026.
• The company has a flexible, global manufacturing strategy to mitigate supply chain risks.
• A recently published meta-analysis ranked pegozafermin among the most effective agents for achieving fibrosis improvement and MASH resolution.

Negatives

• The company reported a net loss of $71.3 million for Q1 2025, compared to a net loss of $51.7 million for Q1 2024.
• Research and development expenses increased to $64.4 million for the three months ended March 31, 2025, compared to $47.4 million for the three months ended March 31, 2024.
• General and administrative expenses increased to $11.5 million for the three months ended March 31, 2025, compared to $9.8 million for the three months ended March 31, 2024.

Risks

• The timing and outcome of the ENLIGHTEN-Fibrosis, ENLIGHTEN-Cirrhosis, and ENTRUST Phase 3 trials are subject to uncertainty.
• The company's success is substantially dependent on the success of its lead product candidate, pegozafermin.
• Competition from competing products poses a risk.
• Changes in FDA or foreign regulatory policies could impact the company.
• The company may need to raise additional capital in the future.

Future Outlook

The company expects topline results from the Phase 3 ENTRUST trial in SHTG in the first quarter of 2026, followed by data readouts from ENLIGHTEN-Fibrosis in the first half of 2027 and ENLIGHTEN-Cirrhosis in 2028, with the latter two intended to support accelerated approval of pegozafermin to treat patients with F2-F3 and compensated F4 MASH.

Management Comments

• 'We have entered 2025 with strong momentum, fueled by continued progress in our two global Phase 3 trials in advanced MASH,' said Rohan Palekar, Chief Executive Officer of 89bio.
• Mr. Palekar added that the company continues to expect topline results from the Phase 3 ENTRUST trial in SHTG in the first quarter of 2026, followed by data readouts from ENLIGHTEN-Fibrosis in the first half of 2027 and ENLIGHTEN-Cirrhosis in 2028.

Industry Context

89bio is developing pegozafermin for MASH and SHTG, diseases with significant unmet needs. The company is positioning pegozafermin as a potentially best-in-class FGF21 analog. The company's progress in Phase 3 trials and strong cash position are important factors in a competitive landscape.

Comparison to Industry Standards

• The meta-analysis in Hepatology ranked pegozafermin among the most effective agents for achieving fibrosis improvement and MASH resolution, suggesting a competitive profile.
• Companies like Madrigal Pharmaceuticals (resmetirom) and Viking Therapeutics (VK2809) are also developing therapies for MASH.
• 89bio's $638.8 million cash position provides a runway to advance its clinical programs, which is a key factor in the biotech industry.

Stakeholder Impact

• Positive for shareholders due to the strong cash position and progress in clinical trials.
• Potential benefit for patients with MASH and SHTG if pegozafermin is approved.
• Impact on employees through continued employment and potential growth of the company.

Next Steps

• Continue enrollment in the Phase 3 ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis trials.
• Await topline data from the Phase 3 ENTRUST trial in SHTG in the first quarter of 2026.
• Prepare for potential accelerated approval filings for pegozafermin in MASH.

Key Dates

Keywords

89bio, Pegozafermin, MASH, SHTG, ENLIGHTEN-Fibrosis, ENLIGHTEN-Cirrhosis, ENTRUST, Clinical Trials, Phase 3, Financial Results, Biopharmaceutical